Trifluoromescaline

Trifluoromescaline (TFM) is a derivative of the phenethylamine psychedelic mescaline, which has a 4-trifluoromethoxy group replacing the 4-methoxy group of mescaline. It was found to be one of the most potent compounds in the scaline series, with a reported dose of 15 to 40 mg (and 60 mg being described as a "strong overdose"), and a slow onset of action and long duration of effects, lasting 14 to 24 hours or more.^[2] The drug showed about 36-fold greater activational potency at the serotonin 5-HT_2A receptor compared to mescaline in vitro.^[3] In addition, it appears to be much more lipophilic than mescaline (predicted log P = 1.9 vs. 0.7, respectively).^[4][5] TFM was first described in the scientific literature by Daniel Trachsel by 2012.^[1][2] Many other related compounds have also been described by Trachsel and colleagues.^[6][1][2]

Trifluoromescaline

Clinical data
Other names	TFM
Routes of administration	Oral[1][2]
Drug class	Serotonergic psychedelic; Hallucinogen
ATC code	None
Identifiers
IUPAC name 2-[3,5-dimethoxy-4-(trifluoromethoxy)phenyl]ethanamine
PubChem CID	155884836
UNII	R4ZT3L7Y4K
CompTox Dashboard (EPA)	DTXSID101045785
Chemical and physical data
Formula	C11H14F3NO3
Molar mass	265.232 g·mol−1
3D model (JSmol)	Interactive image
SMILES COc1cc(CCN)cc(OC)c1OC(F)(F)F
InChI InChI=1S/C11H14F3NO3/c1-16-8-5-7(3-4-15)6-9(17-2)10(8)18-11(12,13)14/h5-6H,3-4,15H2,1-2H3 Key:AVPVNYDXWCNFJD-UHFFFAOYSA-N

See also

• Substituted mescaline analogue
• 2C-TFM
• 2C-TFE
• 2C-T-28
• 2C-T-TFM
• 3C-DFE
• 4-TM
• Allylescaline
• 2-Bromomescaline